GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

E2F AND THE CONTROL OF APOPTOSIS

$201,550
Ohio State University · R01 · FY2003 · CA

E2F AND THE CONTROL OF APOPTOSIS

$201,362
Ohio State University · R01 · FY2000 · CA

Finding the optimal balance of immunotherapy efficacy and toxicity.

$201,354
David Eric Gerber · Ut Southwestern Medical Center · U01 · FY2021 · AI

Role of Polo-like kinase (Plk-1) in Hepatitis B Virus-mediated Hepatocellular Car

$201,300
Ourania M. Andrisani · Purdue University · R21 · FY2009 · CA

CYTOKINE SIGNALING PATHWAYS REGULATING A G1 CHECKPOINT

$201,283
University Of Iowa · R01 · FY2002 · CA

Development of Methods for Precise MR-guided Hyperthermia Delivery for Targeted Cancer Therapies

$201,251
Eugene Ozhinsky · University Of California, San Francisco · R21 · FY2020 · EB

TET2 Regulation of CD8 T cell differentiation During Chronic Viral Infection

$201,250
Martha S Jordan · University Of Pennsylvania · R21 · FY2020 · AI

Mechanisms and strategies to rescue suboptimal T cell priming in colon cancer

$201,042
Peter Maxwell Kienitz Westcott · Cold Spring Harbor Laboratory · K22 · FY2023 · CA

Mechanisms and strategies to rescue suboptimal T cell priming in colon cancer

$201,042
Peter Maxwell Kienitz Westcott · Cold Spring Harbor Laboratory · K22 · FY2025 · CA

Mechanisms and strategies to rescue suboptimal T cell priming in colon cancer

$201,042
Peter Maxwell Kienitz Westcott · Cold Spring Harbor Laboratory · K22 · FY2024 · CA

Systems biology dissection of the road to T cell exhaustion within the tumor microenvironment to identify novel targets for tumor immunotherapy

$200,970
Ann B Hill · Oregon Health & Science University · R21 · FY2018 · CA

Directing Cancer Immunotherapy with Real-Time ImmunoPET

$200,970
Wei-Zen Wei · Wayne State University · R21 · FY2017 · CA

Determining how autophagy mediates resistance to cancer therapies

$200,970
George Victor Thomas · Oregon Health & Science University · R21 · FY2018 · CA

Overcoming resistance to cancer immunotherapy by targeting MDSC-derived adenosine

$200,970
Kavitha Yaddanapudi · University Of Louisville · R21 · FY2020 · CA

Disrupting macrophage metabolism to reduce immunosuppression and enhance therapy in pancreatic cancer

$200,933
Christopher J. Halbrook · University Of California-Irvine · R00 · FY2021 · CA

T cells in the aging brain

$200,720
Anne Brunet · Stanford University · R01 · FY2024 · AG

Immune checkpoint Inhibitor-Induced Autoimmune Diabetes: Immunological Mechanisms and Biomarker Discovery in Provoked Beta Cell Autoimmunity

$200,664
Zoe Quandt · University Of California, San Francisco · K08 · FY2025 · AI

RADIATION INDUCED G1 CHECKPOINT ARREST IN YEAST

$200,632
University Of Chicago · R01 · FY2001 · GM

DC AML Fusion Cell Vaccination with Immune checkpoint Blockade

$200,370
Gordon James Freeman · Dana-Farber Cancer Inst · P50 · FY2020 · CA

A novel IL-2 biologic and tumor immunity

$200,318
Thomas R Malek · University Of Miami School Of Medicine · R21 · FY2017 · CA

Development of Methods for Precise MR-guided Hyperthermia Delivery for Targeted Cancer Therapies

$200,313
Eugene Ozhinsky · University Of California, San Francisco · R21 · FY2019 · EB

Structural studies of molecular cancer targets and drug development

$200,194
David S Waugh · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY

$200,107
Hyun-Sung Lee · Baylor College Of Medicine · R21 · FY2024 · AI

Ipilimumab as an adjuvant for HIV vaccines

$200,007
Mauricio De Aguiar Martins · University Of Miami School Of Medicine · K01 · FY2018 · OD

An Engineered Nanoimmunotherapy for Melanoma

$200,001
Elizabeth E Sweeney · Immunoblue, Llc · R41 · FY2018 · CA